“…In our 45 lesions we achieved no false-negative case; thus, the results of this new system are comparable to other USguided biopsy series with reported sensitivities of 94±100 %, and specificities of 96±98 % [1,4,5,6,7,8]. The question remains as to what other advantages this new dedicated US biopsy system has over conventional US biopsy techniques when the results from all US methods are excellent [1,4,5,6,7,8].…”